24 results about "Signaling transduction" patented technology

Injectable photoelectrohydrogel for repairing retinal photoreceptor damage and its preparation method and application, photoelectroactive spirulina and conductive polymer poly(3,4-ethylenedioxythiophene) (PEDOT) hydrogel are physically cross-linked to construct an injectable material with photoelectric response characteristics, and the function of damaged photoreceptor cells in the retina is repaired in situ. Sp as a biologically active component not only gives the material photoelectric signal conversion capability, but also can achieve local antioxidant stress function, PEDOT-based hydrogel forms a three-dimensional scaffold by physically wrapping Sp, which not only ensures the activity of algal cells but also has excellent charge and ion conduction performance. The hydrogel can be injected into the retina to construct a biomimetic electrochemical signal transmission interface, rebuild the signal transduction of damaged photoreceptor cells, and realize the in situ repair of retinal signal pathways and the partial recovery of visual function. This technology provides a new strategy for the curative treatment of retinal diseases such as blinding eye diseases, and has the advantages of minimally invasive intervention, excellent biocompatibility and customizable treatment area.

The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.The invention further relates to complementary parts of such systems that work best in combination.Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters / sheaths / shafts to yield a robust assessment of cardiac performance.Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.

The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.The invention further relates to complementary parts of such systems that work best in combination.Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters / sheaths / shafts to yield a robust assessment of cardiac performance.Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.

The invention discloses a culture solution for promoting in-vitro maturation of bovine oocytes and application of the culture solution, and belongs to the technical field of assisted reproduction. The invention provides the culture solution which is composed of brand new components and is used for promoting in-vitro maturation of the bovine oocytes, support is provided for maturation of the oocytes from multiple aspects of carrier transportation, energy metabolism regulation, signal transduction, extracellular environment and the like, the in-vitro maturation quality of the bovine oocytes can be effectively promoted, and the survival rate of the bovine oocytes is increased. The quality and consistency of nucleus maturation and cytoplasm maturation of oocytes are obviously improved; the cultured mature oocytes are used for in-vitro fertilization, so that the fertilization proportion and the blastocyst hatching rate can be remarkably improved; the provided culture solution is appropriate in component number, clear in proportion, simple and easy to operate in preparation method, short in time consumption, good in repeatability and suitable for batch production, and has a good application prospect in maturation culture of bovine in-vitro oocytes.

Provided is a chimeric antigen receptor targeting CLL1 and an application thereof. The chimeric antigen receptor targeting CLL1 comprises an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain; the antigen binding domain is an anti-CLL1 antibody. The present application uses an anti-CLL1 antibody as the antigen binding domain to construct a chimeric antigen receptor molecule, the chimeric antigen receptor targeting CLL1 has specific targeting effect on CLL1 positive tumor cells, and immune cells expressing chimeric antigen receptor targeting CLL1 have a significant killing effect in vitro and in vivo, and secrete a large amount of cytokine IFN-γ after co-cultured with CLL1 positive tumor cells, which has a specific clearance effect on CLL1 positive tumor cells.

The invention discloses a CAR-T cell for overexpressing H2A. Z as well as a preparation method and application of the CAR-T cell. In particular, the present invention provides a chimeric antigen receptor comprising an H2A. Z gene or a variant having the same function as the H2A. Z gene. The chimeric antigen receptor further comprises a signal peptide, a CLDN18.2-targeted antigen binding structural domain, a hinge region, a transmembrane region, a co-stimulation structural domain and an intracellular signal transduction structural domain. In a C57BL / 6 mouse model inoculated with CLDN18.2 positive tumor cells MC38-CLDN18.2 and KPC, the treatment effect of the CLDN18.2-CAR-T cell for overexpressing the H2AZ.1 gene disclosed by the invention is obviously superior to that of a CLDN18.2-CAR-T control group without overexpressing the H2AZ.1 gene.

The invention provides an application research of nano layered double hydroxides (LDH) for immunoregulation of interleukin-6 (IL-6) to promote liver regeneration, and based on the biomedical potential of the layered double hydroxide nano material, the action mechanism of the layered double hydroxides nano material in liver regeneration is systematically clarified. According to the application, a potential molecular mechanism of promoting liver regeneration by LDH is disclosed for the first time from the perspectives of immunoregulation and signal transduction, and a new theoretical basis and an experimental basis are provided for application of a nano material in tissue regeneration and liver function reconstruction. In the future, physicochemical properties and targeting of LDH can be further optimized, interaction with immune cells, signal transduction network remodeling and long-term safety of LDH can be deeply discussed in combination with a multi-omics technology and an in-vivo imaging means, and a direction is provided for developing novel immunoregulation type nano-drugs.

This invention belongs to the field of daily chemical products and discloses a polysaccharide composition that improves skin immunity and strengthens the skin barrier function, as well as its applications. The polysaccharide composition includes Scutellaria baicalensis polysaccharide, Adenophora stricta polysaccharide, and Trametes versicolor polysaccharide. Through the synergistic effect of these three polysaccharides, it can not only reduce the number of mast cells but also increase antimicrobial peptides and filaggrin; increase filaggrin; and decrease monocyte chemotactic protein-1 and interleukin-6, thereby achieving the effects of improving skin immunity, anti-inflammatory and whitening. Furthermore, it can act as a signaling molecule, widely participating in physiological processes such as intercellular ligand-receptor recognition and intercellular signal transduction, reducing the average relative amplification fold of interleukin-6 expression factor mRNA, and effectively participating in epidermal cell differentiation and skin barrier formation, thus strengthening the skin barrier function; it can be used in the preparation of cosmetics.

The present disclosure relates to nucleic acid silencing molecules comprising or consisting of a small interfering RNA (siRNA) that reduces the expression of signal transduction and activator of transcription 6 (STAT6). The present disclosure also relates to nucleic acid silencing molecules comprising or consisting of a small interfering RNA (siRNA) that reduces the expression of signal transduction and activator of transcription 6 (STAT6). The disclosure also relates to an in vitro method of reducing STAT6 expression in a cell. The disclosure further relates to methods of treating a disease in a subject comprising administering to the subject a composition comprising the nucleic acid silencing molecule comprising or consisting of a siRNA that reduces the expression of STAT6, and related medical uses.

The present invention relates to a peptide specifically activating signal transduction by targeting fibroblast growth factor receptor (FGFR), an FGFR agonist comprising the peptide, a pharmaceutical composition for preventing or treating diseases associated with decreased FGFR activity, and a cosmetic composition. An FAP1 peptide according to the present invention is a potent FGFR-activating peptide, which exhibited an effective concentration similar to that of bFGF protein, and showed the ability to promote wound healing and support tissue remodeling in vivo. Considering specificity to FGFR and the ability to promote wound healing , FAP1 can be used as a cost-effective alternative to the bFGF protein in therapeutic fields.

The invention relates to chemical compounds useful as structural mimetics of peptides comprising polyproline helix structures, preferably polyproline-type II (PPII) helix structures. The invention further relates to the medical use of the chemical compounds in the treatment of a medical condition associated with a modified intracellular signal transduction process mediated by a poly-proline helix structure and a protein having a binding domain binding to said polyproline helix structure such as an infectious disease, immune disease, neurological disease, cardiometabolic disease and a cancerous disease. The invention further relates to pharmaceutical compositions comprising a compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates to an in vitro method for modifying an intracellular signal transduction process mediated by a poly-proline helix structure, comprising contacting a compound of the invention with a biological cell.

The present application relates to the technical field of cellular immunotherapy, and particularly relates to a kind of targeting PSMA chimeric antigen receptor immune cells and preparation method and application thereof.A kind of targeting PSMA chimeric antigen receptor modified immune effector cell, the chimeric antigen receptor includes antigen binding domain, hinge region, transmembrane domain and signal transduction domain, and the antigen binding domain is anti-PSMA single-chain antibody.The chimeric antigen receptor modified immune effector cell provided in the present application can specifically recognize and combine the antigen binding domain of PSMA, and the prepared chimeric antigen receptor macrophage has specific killing effect on the target cells positive for PSMA protein, and can be used for preparing tumor drugs for treating or preventing PSMA positive.

There are disclosed compounds of the following formula (I): (Formula (I)) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and / or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

The present invention relates to a synthetic cytokine from the IL-6 family. The synthetic cytokine is a polypeptide comprising two binding sites from the same cytokine of the IL-6 family and a third binding site from an additional cytokine of the IL-6 family, wherein the additional cytokine does not require a cytokine-specific non-signaling alpha receptor subunit as part of the receptor complex to trigger signal transduction. All three binding sites of the polypeptide of the present invention must bind to their specific partners to trigger signal transduction. The present invention further relates to a polypeptide for use in medical applications, preferably for the prevention and / or treatment of conditions selected from the group consisting of lymphopenia, muscle atrophy, osteoporosis, thrombocytopenia, obesity-related metabolic disorders such as type II diabetes, obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, hypertension, stroke, or cardiovascular disease, neurological disorders such as paraplegia, Alzheimer's disease, and Parkinson's disease.

The invention belongs to the technical field of biological medicine, and discloses a CCR9-targeted chimeric antigen receptor and application thereof, the chimeric antigen receptor comprises an antigen binding structural domain, a hinge region, a transmembrane structural domain, a co-stimulation structural domain and a signal transduction structural domain which are connected in sequence from N terminal to C terminal; wherein the C end of the signal transduction structural domain is further connected with a CXCR4 chemotactic factor receptor structural domain, and the amino acid sequence of the CXCR4 chemotactic factor receptor structural domain is as shown in SEQ ID NO. 2; the antigen binding structural domain is an anti-CCR9 single-chain variable fragment, and the amino acid sequence of the anti-CCR9 single-chain variable fragment is as shown in SEQ ID NO. 1. The CAR enables immune cells expressing the CAR to obtain stronger tissue chemotactic ability and in-vivo distribution breadth through the energization of CXCR4, and particularly, the ability of the CAR to migrate to bone marrow is remarkably improved, so that the CAR is more beneficial to treatment of acute T lymphocytic leukemia.

Provided are a chimeric protein and a use thereof. The chimeric protein comprises: a transmembrane transport region, a target protein display region, a membrane anchoring region, and an intracellular signal transduction region which are sequentially connected, wherein the transmembrane transport region comprises a transmembrane transport peptide segment; the target protein display region comprises a target protein peptide segment; the membrane anchoring region comprises a membrane anchoring peptide segment; and the intracellular signal transduction region comprises a budding aid peptide segment.

This invention provides an immunomodulatory factor, its preparation method, and its application. The immunomodulatory factor includes: Eotaxin-2, I-309, IL-12p40, IL-12p70, MIG, MIP-1a, TNF-α, AR, BDNF, bFGF, EGF-R, EG-VEGF, IGFBP-6, VEGF, NAP-2, PF4, Activin A, ANG-1, DAN, Follistatin, Galectin-7, ICAM-2, etc. The immunomodulatory factor can be used to prepare immunomodulators, cancer intervention agents, etc., and is of great significance for research on the mechanisms by which thymic mitochondria regulate anti-tumor immunity, including influencing immune cell metabolism, signal transduction, apoptosis, and immune escape.

The present invention aims to provide a method for efficiently producing a cell mass containing pituitary tissue from pluripotent stem cells. A method for producing a cell mass containing pituitary tissue, including the following steps (1) and (2):(1) a first step of suspension-culturing pluripotent stem cells to form a cell aggregate in the presence of a Wnt signal transduction pathway inhibiting substance,(2) a second step of suspension-culturing the aggregate obtained in the first step in the presence of a BMP signal transduction pathway activating substance and a Sonic hedgehog signal transduction pathway activating substance, thereby obtaining a cell mass comprising pituitary tissue.

Disclosed herein are compositions and methods for modulating cell surface receptor signaling by specifically recruiting membrane phosphatases to a proximity of receptors of interest. This novel methodology, termed Receptor Inhibition by Phosphatase Recruitment (RIPR), represents a new approach to reducing and suppressing signal by receptors that signal through phosphorylation mechanisms. More particularly, the disclosure provides novel multivalent protein-binding molecules that specifically bind a cell surface receptor and antagonize the receptor signaling through recruitment of a phosphatase activity. Also provided are compositions and methods useful for producing such molecules, as well as methods for the treatment of diseases associated with the inhibition of signal transduction mediated by cell surface receptor.

The present disclosure provides a chimeric antigen receptor (CAR) immunotherapy for treating a hematologic cancer comprising (a) genetically modifying a population of immune effector cells comprising T cell receptors (TCRs) to stably express at least one CAR, wherein the ectodomain of the CAR specifically binds a cancer antigen; (b) expanding the population of CAR-containing immune effector cells in the presence of one or more cytokines in vitro to achieve a therapeutic dose, wherein the population of CAR-containing immune effector cells exhibits a nonexhausted memory T cell phenotype; and (c) infusing eligible subjects with the CAR-containing immune effector memory T cell phenotype population of cells as needed until the hematologic cancer in the body is destroyed. The intracellular signal transduction domain of the CAR includes 4-1BB, a CD3zeta T cell activation chain and a genetically engineered 'TLE3, which can be ectopically expressed.

The subject invention provides methods for fabricating electrochemical aptamer-based (E-AB) sensors with enhanced sensitivity, signal-to-noise ratios, LOD, and improved stability and reproducibility. The subject invention also provides methods for aptamer immobilization on the surface of the electrode, which favors sufficient spacing between aptamers at the microscale to achieve optimal target recognition, folding, and signal transduction. The E-AB sensors of the subject invention provide superior sensing regardless of the sequence or structure of the bound aptamers or the physiochemical properties of the target.

This invention relates to methods and compositions for regulating the activity of ABCB5+ stem cells. The invention also relates to assays and reagents for manipulating and characterizing compounds that regulate ABCB5+ cell signal transduction.

The invention discloses a chiral bis-pyrene enantiomer crystal and a preparation method and signal conversion application thereof, and relates to the field of CPL signal conversion, and the molecular formula of the chiral bis-pyrene enantiomer crystal is C40H24O2; the chiral bis-pyrene enantiomer crystal comprises (R, R) / (S, S)-CPYM and (R, R) / (S, S)-CPYW, reversible steam-induced conversion from the chiral bis-pyrene enantiomer crystal to a polymorph enables CPL signals to be switched, a powerful strategy is provided for designing a multifunctional chiral material with controllable CPL signals, and the chiral bis-pyrene enantiomer crystal can be used for preparing a chiral material with controllable CPL signals. The eutectic crystal is applied to the fields of photonics and sensing through conformation adjustment in a eutectic system.

The application belongs to the field of biological medicine, and particularly relates to a specific binding protein of IL-4R and a preparation method and application thereof. The application provides a specific binding protein of IL-4R, which has specific CDRs, can be combined with human IL4R alpha with high affinity, and can block the IL4R alpha-IL4 / IL13-IL13R alpha1 interaction and corresponding intracellular signal transduction and biological effects.